Curis to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on March 19, 2026 TrendingStockAlerts · Mar 14, 2026
GenScript Strengthens Transatlantic Biotech Infrastructure with European mRNA Hub TrendingStockAlerts · Mar 13, 2026
Bota Launches SAION AI -- Physical AI Platform for Biomanufacturing TrendingStockAlerts · Mar 12, 2026
LOTTE Biologics to Participate in DCAT Week 2026 in New York to Explore Global Partnership Opportunities TrendingStockAlerts · Mar 10, 2026
U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma TrendingStockAlerts · Mar 9, 2026
Aisa Pharma Announces Encouraging Results from Phase 2 RECONNOITER Trial of AISA-021 (Cilnidipine) in Patients with Systemic Sclerosis-Associated Raynaud's Phenomenon TrendingStockAlerts · Mar 8, 2026
Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line TrendingStockAlerts · Mar 7, 2026
Global Nanomedicine Market is Projected to Cross the USD 550 Billion Mark by 2034 as Advanced Drug Delivery Technologies Accelerate Adoption | DelveInsight TrendingStockAlerts · Mar 6, 2026
ANANDA PHARMA LTD ("Ananda" or the "Company") : MHRA and NHS Ethics Approval Received for ENDOCAN Phase 2 Clinical Trial for Endometriosis TrendingStockAlerts · Mar 5, 2026
Global Implanted Brain-Computer Interface Devices Market to Observe Stupendous Growth at a CAGR of ~10% by 2032 | DelveInsight TrendingStockAlerts · Mar 4, 2026
Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma TrendingStockAlerts · Mar 3, 2026
